Web Analytics
หุ้น HROW (NASDAQ) | HARROW HEALTH INC – วิเคราะห์โดย Deepscope
MARKET

Select Market Data Region

HROW — HARROW HEALTH INC (Healthcare >> Drug Manufacturers - Specialty & Generic)

HROW FAQ

What is HROW's P/E ratio?

HARROW HEALTH INC (HROW) currently trades at a P/E ratio of 102.29.

What is HROW's ROE?

HARROW HEALTH INC reports a Return on Equity (ROE) of -52.12%.

What is HROW's dividend yield?

HARROW HEALTH INC offers a dividend yield of 0.00%.

What is HROW's Deepscope Quality Score?

Deepscope rates HROW's overall financial quality at 54 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy HROW?

Deepscope's AI Timing Score for HROW is 27 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does HROW belong to?

HARROW HEALTH INC is classified under the Healthcare >> Drug Manufacturers - Specialty & Generic sector on the NASDAQ exchange.

Stock Check   *ข้อมูลอัปเดตรายวัน ที่เวลา 09.30 น.*
(Price: 2026-06-05 | FS: 2026-03-31)

USD 33.19
-1.50 (-4.32%) Day Change
102.29
P/E
10.21
D/E
-52.1%
ROE
-3.6%
ROA
0.00%
Div Yield
-5.11
PEG
USD 33.19
Price
-1.50 (-4.32%)
Day Change
NEWS SCORE: 99

HROW มีคุณภาพโดยรวมยังไม่ดีนัก ( คะแนนปัจจัยพื้นฐาน = 54) และ จังหวะเข้าซื้อ ...(ล็อกอินเพื่อดู)...

54

QUALITY

Signal
UNDERPERFORM
Signal Description
Company financial health is Not Good
Reason
P/E ratio ค่อนข้างสูง
อัตราผลตอบแทนผู้ถือหุ้น (ROE) ค่อนข้างต่ำ
อัตราผลตอบแทนสินทรัพย์ (ROA) ค่อนข้างต่ำ
อัตราผลตอบแทนผู้ถือหุ้น (ROE) ในอดีต ค่อนข้างต่ำ
อัตราผลตอบแทนผู้ถือหุ้น (ROE) ลดลงอย่างมีนัยยะสำคัญ
อัตรากำไรสุทธิ ค่อนข้างต่ำ
อัตรากำไรสุทธิในอดีต ค่อนข้างต่ำ

88 Sign in

TIMING

Signal
OUTPERFORM
Signal Descri...
Good
Reason
Lorem ipsum dolor sit amet
Sign in to see timing analysis
Unlock timing signals and detailed reasons
Sign in free

ถ้าดูอย่างละเอียดจะพบว่า ปัจจัยทางคุณภาพ ไม่ดี สุขภาพทางการเงิน ไม่ดี และ ประสิทธิภาพการทำกำไร พอใช้ , ...

ปัจจัยทางคุณภาพ 45%
X
X
X
X
  In Recommendations? Not in any sections
  Select Rate 0.00 From 30 days period
  Watch Rate 0.00 From 30 days period
  News Score 99
  Magic Formula Rank by ROA
N/A
  Magic Formula Rank by ROE
N/A
  Magic Formula Rank by ROIC
N/A
  Price 33.19
  PBV / Sector
45.61 / 2.76
  Earning Per Share -0.38
  PE / Sector
102.29 / 23.64
  PEG or PE/Growth / Sector
-5.11 / 0.13
  Average 1M Daily Value
34.36 M
GREAT
  Average 1W Daily Value
20.65 M
GREAT
ปัจจัยทางเทคนิค 28%
  MACD
  MACD Signal
  MACD Divergence
  RSI
  Stochastic Oscillator K
  Stochastic Oscillator D
  ADX
  Avg 5 day Timing Score
สุขภาพทางการเงิน 41%
X
X
X
X
  DE / Sector
  DE Average / Sector
  DE Change Average (%) / Sector
  Current Ratio / Sector
  Current Ratio Average / Sector
  Current Ratio Change Average (%) / Sector
  Quick Ratio / Sector
  Quick Ratio Average / Sector
  Quick Ratio Change Average (%) / Sector
  FCF/Share / Sector
  FCF/Share Average / Sector
  FCF/Share Change Average (%) / Sector
ประสิทธิภาพการทำกำไร 64%
X
X
X
X
X
X
X
  GPM (%) / Sector
  GPM Average (%) / Sector
  GPM Change Average (%) / Sector
  OPM (%) / Sector
  OPM Average (%) / Sector
  OPM Change Average (%) / Sector
  NPM (%) / Sector
-5.57 / 15.98
  NPM Average (%) / Sector
-10.17 / -16.38
  NPM Change Average (%) / Sector
20.31 / 113.39
GREAT
  Asset Turnover / Sector
  Asset Turnover Average / Sector
  Asset Turnover Change Average (%) / Sector
  ROA (%) / Sector
-3.57 / 8.16
  ROA Average (%) / Sector
-5.23 / 2.38
  ROA Change Average (%) / Sector
12.63 / 108.63
GOOD
  ROE (%) / Sector
-52.12 / -0.19
  ROE Average (%) / Sector
-34.82 / 7.40
  ROE Change Average (%) / Sector
77.37 / 371.95
GREAT
  ROIC (%) / Sector
  ROIC Average (%) / Sector
  ROIC Change Average (%) / Sector
ผลตอบแทนต่อผู้ถือหุ้น 4%
X
  Dividend (%) / Sector
N/A / 0.53
  Dividend Average (%) / Sector
N/A / 3.08
  Dividend Change Average (%) / Sector
N/A / 14.88
รายละเอียดการจดทะเบียน
X
  Analyze Date 2026-06-06 09:08:46
  Symbol HROW
  Name HARROW HEALTH INC
  Sector Healthcare >> Drug Manufacturers - Specialty & Generic
  Market NASDAQ
  Listed Shares 37.28 M
  Par Value N/A
  Calculated From Quarter
  Sign N/A
  Market Cap (M.USD) / Sector Average 1,293.07 / 9,835.56
ข่าว, ประมาณการ, ...
  Estimation Consensus See at WSJ.com
  Full details See at WSJ.com
  Chart See in Chart feature
  News See at Yahoo Finance

Address: 1A Burton Hills Boulevard, Nashville, TN, United States, 37215

Phone: 615 733 4730

Website: https://www.harrow.com

Employees: 373

Sector: Healthcare >> Drug Manufacturers - Specialty & Generic

Description: Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE, as well as BYQLOVI; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; BYOOVIZ, a LUCENTIS biosimilar indicated for the treatment of patients with Neovascular (Wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), and myopic choroidal neovascularization (mCNV); VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; OPUVIZ, an EYLEA biosimilar indicated for the treatment of patients with Wet AMD, macular edema following RVO, diabetic macular edema (DME), and diabetic retinopathy (DR); MAXIDEX and FLAREX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe and the eye; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and NATACYN, a sterile, antifungal drug for the treatment of fungal blepharitis, conjunctivitis, and keratitis. In addition, it offers TOBRADEX ST, a tobramycin and dexamethasone ophthalmic suspension; VERKAZIA cyclosporine ophthalmic emulsion; NEVANAC, a non-steroidal, anti-inflammatory eye drop; and FRESHKOTE preservative free (PF) is a lubricant eye drop. The company was formerly known as Harrow Health, Inc. and changed its name to Harrow, Inc. in September 2023. Harrow, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee.

ME vs SECTOR Healthcare >> Drug Manufacturers - Specialty & Generic

HROW (ME)
Sector Peers
Bubble size = Market Cap

Click a bubble to view stock details  ·  Bubble size represents market capitalization share

News

Smart picks. Just WOW stocks/funds/ETFs. No noise like other tools.
HROW
HROW
USD 33.19 (-4.32%)
+ Watch + Port Chart